Results 121 to 130 of about 25,866 (210)

SGSS05-NS3, a covalent SETD8 inhibitor that activates p53 pathway in neuroblastoma. [PDF]

J Exp Clin Cancer Res
Liu Z, Bagchi S, Yan C, Hu Y, Blum G, Ma A, Jin J, Luo M, Di Bella S, Verona F, Appella E, Giannini G, Thiele CJ, Veschi V.   +13 more
europepmc   +1 more source

Targeted CRISPR knockout screening identifies known and novel chemogenomic interactions between DNA damaging agents and DNA repair genes. [PDF]

NAR Cancer
Heer CD, Elia JL, Menon V, Johnson SS, Arbelaez SR, Friedman S, Lopez-Giraldez F, Sundaram RK, Herzon SB, Bindra RS, Gueble SE.   +10 more
europepmc   +1 more source

Validating TDP1 as an Inhibition Target for Lipophilic Nucleoside Derivative in Human Cells. [PDF]

Int J Mol Sci
Chernyshova IA, Kornienko TE, Dyrkheeva NS, Zakharenko AL, Chepanova AA, Orishchenko KE, Kurochkin NN, Drenichev MS, Lavrik OI.   +8 more
europepmc   +1 more source

Transcriptomic Analysis of TDP1-Knockout HEK293A Cells Treated with the TDP1 Inhibitor (Usnic Acid Derivative). [PDF]

Int J Mol Sci
Zakharenko AL, Dyrkheeva NS, Markov AV, Kleshchev MA, Ryabchikova EI, Malakhova AA, Orishchenko KE, Okorokova LS, Shtokalo DN, Medvedev SP, Zakian SM, Tupikin AA, Kabilov MR, Luzina OA, Deyev SM, Lavrik OI.   +15 more
europepmc   +1 more source

Survival Benefit of Temozolomide Plus Irinotecan as Second-Line Therapy in Small Cell Lung Cancer: A Retrospective Single-Center Study. [PDF]

J Clin Med
Acar O, Agaoglu AB, Sahbazlar M, Ekinci F, Erdogan AP.   +4 more
europepmc   +1 more source

Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial. [PDF]

Nat Cancer
Yuan G, Lou G, Li J, Xu M, Liu X, Wang D, Zhang K, Zhu T, Li X, Huang Y, Duan W, Wang K, Zhou Q, Li G, Yang C, Zhang J, Sun H, Tang R, Li Q, Wu L.   +19 more
europepmc   +1 more source

State of the art in treatment of small cell lung cancer. [PDF]

Ther Adv Med Oncol
Behrouzi R, Blackhall F.
europepmc   +1 more source

Intraocular Pressure Changes following Intravitreal Topotecan 90 μg/0.18 cc for the Treatment of Retinoblastoma. [PDF]

Ocul Oncol Pathol
Law CW, Francis JH, Abramson DH.
europepmc   +1 more source

A selective RPL15 PROTAC degrader enhances anti-PD-1 immunotherapy in a murine melanoma tumor model. [PDF]

Oncogene
Takahashi R, Yamamoto K, Toya H, Shoji H, Kawanishi K, Momosaki K, Yabe M, Takashima K, Muromoto R, Ichikawa S, Matsuda T, Kitai Y.   +11 more
europepmc   +1 more source

Management and survival outcomes of desmoplastic small round cell tumor: a retrospective cohort study from a tertiary cancer center. [PDF]

BMC Cancer
Sundaramoorthy S, Abraham G, Narayanan G, Nair SG, Purushothaman PN, Thambi SM, Mathew SP, Philip DSJ, Nair S, Muthukumarasamy T.   +9 more
europepmc   +1 more source